Navigation Links
The Astellas European Foundation Winner of Transplantation Grant 2011 Announced
Date:9/6/2011

GLASGOW, Scotland, September 7, 2011 /PRNewswire/ --

The Astellas European Foundation is delighted to announce the winner of the 2011 Transplantation Grant:

Dr Christian Toso of the University of Geneva, Switzerland

Last evening, the University's team, led by Dr Toso, received the grant of US$ 300,000 to support work on their project entitled 'Towards a tailored immuno-suppression after liver transplantation for hepatocellular carcinoma' at the Astellas European Foundation Award presentation.

Dr Ayad Abdulahad, Astellas European Foundation Trustee and Vice President Medical Affairs and Health Economics for Astellas Pharma Europe Ltd. commented, "We received many entries of a very high standard which covered a broad range of topics across Europe.  In the face of very strong competition the Jury chose Dr Toso's research based on its potential impact on clinical practice.  The team's aim is to tailor immunosuppressive strategy for individual patients with hepatocellular carcinoma. It is very exciting and, in the future, their results could possibly be applied to other cancers."

At the Award Presentation Event in Glasgow, UK, the Astellas European Foundation emphasised their continued and long term commitment to research and development in the field of transplant medicine.

Dr Toso said, "We thank the Astellas European Foundation for its generous support. Although liver transplantation is the most efficient treatment for patients with early  unresectable hepatocellular carcinoma, some 10% of recipients still experience recurrence after transplantation. The aim of our study is to define the ideal immunosuppression strategy, both clearing cancer cells and preventing rejection. Such a study has the potential to better tailor immunosuppression after liver transplantation for cancer, improve outcomes and qualify some currently excluded patients with more advanced HCCs for transplantation."

The Astellas European Foundation is a registered charity. It was established in 2005 with the  goal of providing support for programmes and activities that contribute to the advancement of an increasingly healthy society. The Astellas European Foundation Transplantation Grant supports basic medical and related scientific programmes which contribute to advancements in transplant medicine.  The winner of the grant was chosen by a Jury that includes independent European transplantation leaders.

http://www.astellas.com/eu


Notes to Editors

About The Astellas European Foundation

The Astellas European Foundation is a registered charity, established in 2005, with the long-term goal of providing support for programmes and activities that contribute to the advancement of an increasingly healthy society. The Astellas European Foundation is registered with the Charity Commission for England and Wales with number 1036344.

About Astellas Pharma Europe Ltd.

Astellas Pharma Europe Ltd., located in the UK, is a European subsidiary of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. The organisation is committed to becoming a global company by combining outstanding R&D and marketing capabilities and continuing to grow in the world pharmaceutical market. Astellas Pharma Europe Ltd. is responsible for 21 affiliate offices located across Europe, the Middle East, and Africa, an R&D site, and three manufacturing plants. The company employs approximately 4,000 staff across these regions.



'/>"/>
SOURCE Astellas European Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
2. Ironwood and Astellas Announce Japan Licensing Agreement for Linaclotide
3. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
4. Ambit Biosciences and Astellas Enter Strategic Partnership to Research, Develop and Commercialize FLT3 Kinase Inhibitors in Multiple Indications
5. Astellas Announces Full Slate of Independent Director Nominees for Election at OSI Pharmaceuticals 2010 Annual Stockholders Meeting
6. Astellas Announces Successful Completion of Initial Tender Offer for Shares of OSI and Announces Subsequent Offer Period
7. Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
8. Astellas Awards Scholarships to 12 Transplant Recipients and Donors Who Embody Hope, Courage and Achievement
9. Astellas Mobilizes 1,300+ Employees in the Americas to Participate in First Annual Changing Tomorrow Day
10. Although NeurogesX/Astellass Qutenza is Only Approved for Postherpetic Neuralgia, Surveyed U.S. Physicians are Likely to Prescribe It for All Neuropathic Pain Types
11. Astellas Announces Retirement of Donald Rice and Appointment of Sef Kurstjens as CEO and President of Agensys, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/24/2016)... KNOXVILLE, Tenn. , June 24, 2016 /PRNewswire/ ... market providing less invasive and more durable cerebrospinal ... million in funding.  The Series-A funding is led ... the Lighthouse Fund, and other private investors.  Arkis, ... less-invasive neurosurgical instrumentation and the market release of ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... Dallas, Texas (PRWEB) , ... June 24, 2016 ... ... 12th International Conference and Scientific Sessions in Dallas that it will receive two ... Announcement of the grants came as PHA marked its 25th anniversary by recognizing ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):